Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

HighTide Therapeutics Inc (2511)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.29 -0.20    -5.73%
31/07 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4568L1023 
  • Volume: 1,597,000
  • Bid/Ask: 3.27 / 3.29
  • Day's Range: 3.26 - 3.53
HighTide Therapeutics 3.29 -0.20 -5.73%

HighTide Therapeutics Inc Company Profile

 
Get an in-depth profile of HighTide Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

70

Equity Type

ORD

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as in phase II clinical trial to treat primary biliary cholangitis. The company is also developing HTD4010, a polypeptide drug, which is in phase I clinical trial for the treatment of alcoholic hepatitis; HTD1804 that is in preclinical trial to treat obesity; HTD1805, a multifunctional small molecule drug, which is in preclinical trial for the treatment of metabolic diseases; HTF1057 a preclinical-stage a drug candidate for the treatment of neurodegenerative diseases; HTF1037 a preclinical-stage for the treatment of obesity and comorbidities; and HTD2802 that is in preclinical trial for treating inflammatory bowel disease. HighTide Therapeutics, Inc. was founded in 2011 and is headquartered in Shenzhen, China.

Contact Information

Address Shenzhen-Hong Kong Floor 9 to 10, Building D
Science and Technology Innovation Cooperation Zn Fubao Community, Fubao Sub-district, Futian Distri
China
Phone 86 755 2662 6253
Fax -

Top Executives

Name Age Since Title
Lawrence Goldkind - - Member of Scientific Advisory Board
Gwen A. Melincoff 73 - Member of the Scientific Advisory Board
Kris Kowdley - - Member of Scientific Advisory Board
Adrian M. Di Bisceglie - - Member of Scientific Advisory Board
Lixiong Ma 50 2021 Deputy Chairman of the Board
Liping Liu 55 2018 CEO & Chairwoman
Li Jin 59 2023 Independent Non-Executive Director
Meng Yu 43 2017 Deputy GM & Executive Director
Tak Wai Hung 66 2023 Independent Non-Executive Director
Xun Zhu 67 2020 Non-Executive Director
Bo Tan 52 2023 Independent Non-Executive Director
Feng Jiang 45 2022 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2511 Comments

Write your thoughts about HighTide Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email